H2G
0.006
100%
88E
0.001
-50%
SFG
0.002
100%
NRZ
0.001
-50%
RLT
0.75
66.7%
ALM
0.003
-40%
ERA
0.003
50%
ASP
0.003
-40%
GTR
0.003
50%
GT1
0.04
-31%
JAV
0.003
50%
CKA
0.036
-29.4%
BEZ
0.037
32.1%
TOU
0.008
-27.3%
COB
0.069
25.5%
BP8
0.003
-25%
CXU
0.01
25%
BUY
0.003
-25%
LEG
0.01
25%
TMK
0.003
-25%
MEG
0.015
25%
BSX
0.057
-23%
NAE
0.005
25%
PUA
0.007
-22.2%
IVX
0.13
23.8%
RB6
0.09
-18.2%
RAS
0.021
23.5%
PLN
0.12
-17.2%
MLX
0.665
22%
OVT
0.005
-16.7%
ELT
0.061
22%
IFG
0.012
-14.3%
SRZ
0.017
21.4%
OEC
0.09
-14.3%
RAC
1.25
21.4%
CBL
0.037
-14%
ROG
0.006
20%
REZ
0.019
-13.6%
SRI
0.012
20%
RIM
0.026
-13.3%

PharmAust (ASX:PAA): Extension study begins

Clinical-stage biotechnology company, PharmAust (ASX:PAA), announces that the first patient has been dosed in the Open-Label Extension study at Calvary Health Care Bethlehem, which will investigate the long-term safety, tolerability and efficacy of monepantel in patients with Motor Neurone Disease.

ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02772313-6A1193834

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved